Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when ...

Cybin launches Phase 3 trials for CYB003, aiming to offer lasting relief for Major Depressive Disorder. Backed by promising ...

Psilocybin-assisted therapy could potentially benefit up to 5.6 million Americans with major depressive disorder or treatment ...

Acupuncture. Ketamine infusions. "Electroshock" or electroconvulsive therapy. The existing treatment options for those ...

Neumora Therapeutics, Inc. (NMRA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

Cybin (Cboe CA:CYBN) has begun its Phase 3 pivotal program, PARADIGM, to evaluate the efficacy and safety of CYB003 as an ...

Patients with non-seasonal depression who were treated with bright light therapy reported a 40% remission rate, according to a recent study.

The weight loss injection tirzepatide helped Melanie Ressa lose weight and overcome food noise, emotional eating, and mental ...

Major depressive disorder (MDD) is a chronic and recurrent mental condition leading to huge impacts on direct and indirect personal and public medical costs. To overcome such a serious mental ...

After working at a crowded and dangerous internment camp in Iraq, Air Force Staff Sgt. Heather O’Brien brought home with her ...

The Food and Drug Administration (FDA) has cleared Magstim’s Horizon ® 3.0 Inspire for the treatment of major depressive disorder (MDD) in adults who have failed to achieve satisfactory improvement ...

Bipolar disorder is a long-term mood disorder characterized by major fluctuations in mood — both high and low — that can ...